Palatin Technologies (PTN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
25 Jun, 2026Executive summary
Annual meeting scheduled for July 28, 2026, will be held virtually to enhance accessibility and participation for all shareholders.
Key business items include election of four directors, ratification of KPMG LLP as auditor, amendment to the 2011 Stock Incentive Plan, and advisory vote on executive compensation.
Shareholders of record as of June 22, 2026, are eligible to vote; multiple classes of stock have different voting powers.
Proxy materials are distributed both in print and online, with procedures for proxy voting, revocation, and confidentiality outlined.
Voting matters and shareholder proposals
Four directors are nominated for election; voting is by plurality.
Ratification of KPMG LLP as independent auditor for fiscal year ending June 30, 2026, is proposed.
Amendment to the 2011 Stock Incentive Plan seeks to increase shares reserved for issuance by 260,000 and make other clarifications.
Advisory, non-binding vote on executive compensation (say-on-pay) is included.
Shareholder proposals for the next annual meeting must be submitted by February 22, 2027.
Board of directors and corporate governance
Board consists of four nominees, with a mix of scientific, business, and industry expertise.
All directors except the CEO are independent under NYSE and Nasdaq standards.
Board committees include audit, compensation, and nominating/corporate governance, each composed of independent directors.
Board leadership is separated between the Chairman and CEO roles.
Code of corporate conduct and ethics applies to all directors, officers, and employees.
Latest events from Palatin Technologies
- Next-gen MC4R agonists for rare obesity syndromes advance toward clinical trials in 2026–2027.PTN
Corporate presentation31 May 2026 - Advancing selective MC4R agonists for rare obesity, with key clinical and partnership milestones ahead.PTN
Corporate presentation18 May 2026 - Licensing revenue growth and pipeline progress support operations through mid-2027.PTN
Q3 202613 May 2026 - MC4R-based obesity pipeline advances with strong cash reserves and key clinical milestones ahead.PTN
Q2 202611 Apr 2026 - Advancing MC4R agonists for rare obesity, with strong pipeline and strategic partnerships.PTN
Corporate presentation16 Mar 2026 - Advancing MC4R agonists for rare obesity and forging key partnerships for future growth.PTN
Corporate presentation17 Feb 2026 - Net loss of $29.7M, asset sale, and pipeline progress set stage for key 2024–2025 milestones.PTN
Q4 202419 Jan 2026 - No product revenue, $7.8M net loss, and a strategic pivot to obesity programs with key data due in 2025.PTN
Q1 202514 Jan 2026 - Net loss narrowed, no product revenue, and liquidity risks persist amid advancing clinical programs.PTN
Q2 202524 Dec 2025